Medtronic beats, but the stock drops on guidance and cost headlines

What happened

Medtronic ($MDT) beat quarterly profit expectations on strong demand for cardiovascular devices (notably cardiac ablation / PFA) and solid procedure volumes, but shares slipped after the company kept full-year EPS guidance unchanged and flagged cost headwinds (tax, tariffs).

Why markets care

This is a “demand is strong, but the bar is higher” print. It supports the theme that procedure volumes are healthy across medtech, yet investors are quick to punish conservative guidance and cost uncertainty.

Winners

Cardiac ablation and electrophysiology momentum (procedure growth + tech upgrade cycle)

Strong cardiac ablation growth signals healthy elective/procedure demand and a continuing upgrade cycle in AFib tr ...